Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources.

Bayesian Designs for Phase I II Clinical Trials describes how phase I II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory...

This book provides a comprehensive review of novel adaptive trial designs for targeted therapies and immunotherapies. This book covers a wide range of novel statistical designs for various clinical settings, including early phase dose-escalation study, proof-of-concept trials, and confirmatory studies with registrational. The book includes real-life examples and software to facilitate practitioners to learn and use the designs in practice.

This book provides a comprehensive review of novel adaptive trial designs for targeted therapies and immunotherapies. This book covers a wide range of novel statistical designs for various clinical settings, including early phase dose-escalation study, proof-of-concept trials, and confirmatory studies with registrational. The book includes real-life examples and software to facilitate practitioners to learn and use the designs in practice.